10 Pharmaceutical Stocks to Buy According to Brandon Haley's Holocene Advisors
In this article, we take a look at the 10 pharmaceutical stocks to buy according to Brandon Haley’s Holocene Advisors.
Established in Q3 of 2016, Holocene Advisors is a prominent hedge fund manager based in New York, led by Brandon Haley, former global head of equities at Citadel. The firm employs a sector-diversified long/short equity strategy, aiming to generate alpha through rigorous fundamental research conducted by specialized investment teams.
Brandon Haley serves as the Founder and CEO of Holocene Advisors, LP, drawing on extensive experience from his tenure at Citadel Investment Group, Northsound Capital, and Goldman Sachs. Brandon Haley is an alumnus of McGill University, where he studied from 1995 to 1999.
Holocene Advisors, a leading hedge fund, manages assets for 7 clients with discretionary assets under management (AUM) totaling $36,691,670,383. Their latest 13F filing for Q1 2024 reported managing $27,231,538,385 in 13F securities, with a top 10 holdings concentration of 14.36%. Notably, Holocene Advisors's largest holding comprises 3,789,733 shares of Amazon.com Inc.
